Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Simes

Showing results (21-30 of 265) with videos related to

Pageof 27
Sort By:
Lancet (London, England)|June 15, 2020
Questioning statin therapy for older patients - Authors' replyJordan Fulcher, Anthony Keech, John Simes, et al.
Journal of the National Cancer Institute|January 5, 2006
Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspectiveVal Gebski, Marivic Lagleva, Anthony Keech, et al.
International Journal of Technology Assessment in Health Care|January 11, 2012
Linking the evidence: intermediate outcomes in medical test assessmentsLukas P Staub, Suzanne Dyer, Sarah J Lord, et al.
Asia-Pacific Journal of Clinical Oncology|May 30, 2013
Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care studyJames Y Chen, Elizabeth Hovey, Mark Rosenthal, et al.
The Medical Journal of Australia|June 3, 2009
Molecular biomarkers to individualise treatment: assessing the evidenceChee K Lee, Sarah J Lord, Alan S Coates, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancerPeter S Grimison, R John Simes, H Malcolm Hudson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Deriving a patient-based utility index from a cancer-specific quality of life questionnairePeter S Grimison, R John Simes, H Malcolm Hudson, et al.
Australian and New Zealand Journal of Public Health|January 7, 2004
The benefits and costs of tamoxifen for breast cancer preventionSimon D Eckermann, Andrew J Martin, Martin R Stockler, et al.
The Cochrane Database of Systematic Reviews|November 28, 2018
Anti-angiogenic therapy for high-grade gliomaMalaka Ameratunga, Nick Pavlakis, Helen Wheeler, et al.
Cancer Reports (Hoboken, N.J.)|December 17, 2025
Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI TherapyMeghana Maddula, Annelise Decaria, Bea Brown, et al.
Pageof 27

Showing results (21-30 of 265) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|June 15, 2020
Questioning statin therapy for older patients - Authors' replyJordan Fulcher, Anthony Keech, John Simes, et al.
Journal of the National Cancer Institute|January 5, 2006
Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspectiveVal Gebski, Marivic Lagleva, Anthony Keech, et al.
International Journal of Technology Assessment in Health Care|January 11, 2012
Linking the evidence: intermediate outcomes in medical test assessmentsLukas P Staub, Suzanne Dyer, Sarah J Lord, et al.
Asia-Pacific Journal of Clinical Oncology|May 30, 2013
Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care studyJames Y Chen, Elizabeth Hovey, Mark Rosenthal, et al.
The Medical Journal of Australia|June 3, 2009
Molecular biomarkers to individualise treatment: assessing the evidenceChee K Lee, Sarah J Lord, Alan S Coates, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancerPeter S Grimison, R John Simes, H Malcolm Hudson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Deriving a patient-based utility index from a cancer-specific quality of life questionnairePeter S Grimison, R John Simes, H Malcolm Hudson, et al.
Australian and New Zealand Journal of Public Health|January 7, 2004
The benefits and costs of tamoxifen for breast cancer preventionSimon D Eckermann, Andrew J Martin, Martin R Stockler, et al.
The Cochrane Database of Systematic Reviews|November 28, 2018
Anti-angiogenic therapy for high-grade gliomaMalaka Ameratunga, Nick Pavlakis, Helen Wheeler, et al.
Cancer Reports (Hoboken, N.J.)|December 17, 2025
Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI TherapyMeghana Maddula, Annelise Decaria, Bea Brown, et al.
Pageof 27